Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:21:48.534Z.
Calculation as of: 2026-10-06T19:21:48.534Z.
Quote observation: 2026-10-06T19:20:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1e37222dd90dbab5e03bfa1bbf20eaf6e61690ec1e62f49524765e66f30de265
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$38.96M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$38.77M
Price/OCF Ratio
59.73
TTM Avg
12.39
3Y Avg
12.73
5Y Avg
32.12
Market Cap
$42.46M
Price/OCF Ratio
N/A
TTM Avg
9.67
3Y Avg
15.53
5Y Avg
36.04
Market Cap
$37.72M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Filana Therapeutics, Inc. (FLNA) | $40.53M | N/A | N/A | N/A | N/A |
| Veru Inc. (VERU)vs › | $39.56M | N/A | 6434.79 | 6434.79 | 3026.88 |
| Precipio, Inc. (PRPO)vs › | $41.95M | 38.14 | 48.39 | 39.24 | 39.24 |
| Metagenomi, Inc. Common Stock (MGX)vs › | $38.96M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.77M | 59.73 | 12.39 | 12.73 | 32.12 |
| BioStem Technologies, Inc. (BSEM)vs › | $42.46M | N/A | 9.67 | 15.53 | 36.04 |
| Nano-X Imaging Ltd. (NNOX)vs › | $42.83M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $38.11M | N/A | 33.35 | 46.22 | 46.22 |
| Incannex Healthcare Limited (IXHL)vs › | $37.72M | N/A | N/A | N/A | N/A |
| CVRx, Inc. (CVRX)vs › | $43.52M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
